TokenPost·
Palvella Announces FDA Priority Review for Qtorin Rapamycin Application
The application seeks U.S. approval for the topical candidate, and Palvella shares traded higher Wednesday.
More news
- Crypto BriefingGoogle deepens Anthropic TPU partnership as Broadcom locks in chip supply through 2031
- Crypto BriefingAlphabet reaffirms $195 billion to $205 billion capex guidance as AI spending climbs
- TokenPostYield Fields Reports 3,333-Deed Sellout; SafZ Criticizes Game Similarities
- TokenPostPost Claims TXFlow Is a Hyperliquid Fork, Raising Questions
- CoinDeskBitcoin-backed mortgages are coming to Canada, but borrowers are still unaware of the cost
- TokenPostBaker Hughes Profit Falls 33% as Chart Industries Lifts Revenue